# Yonjin Venture

> Yonjin Venture is a VC fund backing Health Care and Biotechnology. See 25 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 25
- Last investment: Sep 2025
- Lead investor: 20%
- Last updated: Aug 2026
- Website: http://www.yjventure.com

Yonjin Venture is an investment firm specializing in investing in early and mid-stage life science companies.It focuses on the innovative technologies in therapeutics, diagnostics, and medical devices. The firm is a sub-organization of Yongjin Group and the sister firm of Yonghua Capital.The Cambridge, Massachusetts-based firm was establishedin 2018.

## Contacts

5 contacts available for Yonjin Venture. Shizune tracks 8 team members at Yonjin Venture. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/yonjin-venture?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 13 | 52% |
| Biotechnology | 13 | 52% |
| Medical | 7 | 28% |
| Medical Device | 5 | 20% |
| Therapeutics | 4 | 16% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 7 | 28% |
| Series B | 6 | 24% |
| Series C | 4 | 16% |
| Series D | 2 | 8% |
| Funding Round | 2 | 8% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 14 | 56% |
| China | 1 | 4% |
| Israel | 1 | 4% |
| Belgium | 1 | 4% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Chong Wang | Executive Director | 0 | https://shizune.co/investors/profile/chong-wang-9245 |
| Daguan Wang | Managing Director | 4 | https://shizune.co/investors/profile/daguang-wang |
| Fanbo Meng | Executive Director | 0 | https://shizune.co/investors/profile/fanbo-meng-816b |
| Gary Yang | Partner | 0 | https://shizune.co/investors/profile/gary-yang-8f84 |
| Qiong Ye | Vice President | 0 | https://shizune.co/investors/profile/qiong-ye |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rapafusyn Pharmaceuticals | Rapafusyn Pharmaceuticals licenses technology related to a novel class of natural product-like macrocycle. The company develops novel pharmaceuticals to treat patients having diseases and fulfill other unmet medical needs. | $16M | Series A | Sep 04, 2025 |  |
| HistoSonics | HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. |  | Private Equity | Aug 07, 2025 |  |
| TECLens | TECLens is creating a crosslinking technology that may accurately fix vision issues in healthy eyes as well as treat keratoconus. It provides patients with presbyopia with the ability to regain their ability to read at a distance, controls children's progressive myopia, corrects adult vision problems like hyperopia and low-order myopia, andmore. | $9.3M | Series A | Feb 11, 2025 |  |
| CSA Medical | CSA Medical provides cryotherapy systems. It offers CryoSpray Ablation system, which enables the physicians to freeze, destroy, and remove unwanted tissues, as well as transports liquid nitrogen that is passed through a standard endoscope. CSA Medical was formerly known as Crymed Technologies and changed its name to CSA Medical in April 2006.Thecompany was incorporated in 1993 and is based in Lutherville Timonium, Maryland. | $53M | Series D | Sep 09, 2024 |  |
| HistoSonics | HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $102M | Series D | Aug 15, 2024 |  |
| EvolveImmune Therapeutics | EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generatefirst-in-class treatments for unmet needs in oncology and autoimmune diseases. | $37.4M | Venture - Series Unknown | Nov 16, 2023 |  |
| HistoSonics | HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $85M | Convertible Note | Dec 13, 2022 |  |
| Intressa Vascular | Intressa Vascular provides innovative solutions to address life-threatening cardiovascular conditions such as aortic dissection. | $12M |  | Oct 25, 2022 |  |
| Bluejay Therapeutics | Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate offunctional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients. | $41M | Series B | Aug 16, 2022 |  |
| Regenacy Pharmaceuticals | Regenacy Pharmaceuticals they give services to treat diabetic and other peripheral neuropathies. | $9.3M | Series B | Aug 15, 2022 |  |

10 of 25 investments shown.

## Co-investors
- [Johnson & Johnson Innovation](https://shizune.co/investors/profile/johnson-johnson-innovation-jjdc) — VC Fund, 5 deals together
- [3E Bioventures](https://shizune.co/investors/profile/3e-bioventures) — VC Fund, 4 deals together
- [Cobro Ventures](https://shizune.co/investors/profile/cobro-ventures) — VC Fund, 4 deals together
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 4 deals together
- [State of Wisconsin Investment Board](https://shizune.co/investors/profile/state-of-wisconsin-investment-board) — VC Fund, 4 deals together
- [Taiwania Capital Management Corporation](https://shizune.co/investors/profile/taiwania-capital) — VC Fund, 4 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Belgium](https://shizune.co/investors/medical-vc-funds-belgium)

## FAQ

### What does Yonjin Venture invest in?

Yonjin Venture invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Yonjin Venture?

Public channels for Yonjin Venture include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Yonjin Venture?

The team at Yonjin Venture includes Chong Wang (Executive Director), Daguan Wang (Managing Director) and Fanbo Meng (Executive Director), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co